PE20020434A1 - Metodo de tratamiento de la enfermedad de parkinson - Google Patents
Metodo de tratamiento de la enfermedad de parkinsonInfo
- Publication number
- PE20020434A1 PE20020434A1 PE2001001012A PE2001001012A PE20020434A1 PE 20020434 A1 PE20020434 A1 PE 20020434A1 PE 2001001012 A PE2001001012 A PE 2001001012A PE 2001001012 A PE2001001012 A PE 2001001012A PE 20020434 A1 PE20020434 A1 PE 20020434A1
- Authority
- PE
- Peru
- Prior art keywords
- cycloalkyl
- alkyl
- parkinson
- disease
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A UN METODO PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON QUE COMPRENDE ADMINISTRAR EN FORMA CONCOMITANTE: a) DE 1mg A 2000 mg DEL COMPUESTO DE FORMULA I O FENILAZACICLOALCANO SUSTITUIDO DONDE n ES 1-2; R1 Y R2 SON INDEPENDIENTEMENTE H, SIEMPRE QUE AMBOS NO SEAN H, OH, CH, CH2CN, 2- O 4-CF3, CH2,CF3, CH2CHF2, CH=CF2, ETENILO, ENTRE OTROS; R3 ES H, CF3, CH2CF3, ALQUILO C1-C8, CICLOALQUILO C3-C8, CICLOALQUIL-METILO C4-C9, ALQUENILO C2-C8, ENTRE OTROS; R4 Y R SON H, CF3, CH2CF3, ALQUILO C1-C8, CICLOALQUILO C3-C8, ENTRE OTROS. UN COMPUESTO PREFERIDO ES (S)-(-)-3-METILSULFONILFENIL-1-PROPILPIPERIDINA; b) UN AGONISTA DE DOPAMINA L-DOPA SELECCIONADO DE APOMORFINA, BROMOCRIPTINA, PERGOLIDA, ROPINIROL, PRAMIPEXOL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23982800P | 2000-10-12 | 2000-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020434A1 true PE20020434A1 (es) | 2002-06-17 |
Family
ID=22903911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001012A PE20020434A1 (es) | 2000-10-12 | 2001-10-12 | Metodo de tratamiento de la enfermedad de parkinson |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6653325B2 (es) |
| EP (1) | EP1404326A4 (es) |
| JP (1) | JP2004528283A (es) |
| AU (1) | AU2002246490A1 (es) |
| CA (1) | CA2425125A1 (es) |
| PE (1) | PE20020434A1 (es) |
| WO (1) | WO2002056745A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| PT2561860T (pt) * | 2002-05-31 | 2018-05-08 | Titan Pharmaceuticals Inc | Dispositivo polimérico implantável para a libertação prolongada de buprenorfina |
| EP1610791B1 (en) * | 2003-03-31 | 2011-02-23 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of dopamine agonist |
| US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
| WO2004100929A1 (en) | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
| US20070010584A1 (en) * | 2003-09-04 | 2007-01-11 | Peroutka Stephen J | Compositions and methods for orthostatic intolerance |
| US20080038198A1 (en) * | 2004-01-05 | 2008-02-14 | Mitsubishi Pharma Corporation | Method Of Screening Molecule Associated With Psychiatric Disorder |
| ES2383768T3 (es) * | 2006-06-28 | 2012-06-26 | Chelsea Therapeutics Inc. | Composiciones farmacéuticas que comprenden droxidopa |
| TW200815045A (en) * | 2006-06-29 | 2008-04-01 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of ropinirole and methods of use thereof |
| JP2010520885A (ja) * | 2007-03-09 | 2010-06-17 | チェルシー・セラピューティクス，インコーポレイテッド | 線維筋痛症の治療のためのドロキシドパ及びその医薬組成物 |
| WO2008137923A2 (en) * | 2007-05-07 | 2008-11-13 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| ES2528040T3 (es) * | 2007-06-18 | 2015-02-03 | A.Carlsson Research Ab | Uso de estabilizadores de dopamina |
| JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状（姿勢反射異常）の治療剤 |
| US11209426B2 (en) * | 2011-12-07 | 2021-12-28 | Board Of Regents Of The University Of Nebraska | Method for diagnosing and treating Parkinson's disease via measurment of effector memory t-cells |
| WO2014172372A1 (en) | 2013-04-15 | 2014-10-23 | Northwestern University | Treatment for dopaminergic disorders |
| US10751328B2 (en) * | 2013-10-25 | 2020-08-25 | Oral Alpan | Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU653837B2 (en) * | 1991-04-17 | 1994-10-13 | Pharmacia & Upjohn Company | Substituted phenylazacycloalkanes as CNS agents |
| SE9702716D0 (sv) * | 1997-07-15 | 1997-07-15 | Ross Nicholas Waters | Substituted phenylazacycloalkanes in the treatment of cognitive disorders |
| SE9802546D0 (sv) * | 1998-07-15 | 1998-07-15 | Ross Nicholas Waters | Medicinal product and method for treatment and prevention of dyskinesia |
-
2001
- 2001-10-12 PE PE2001001012A patent/PE20020434A1/es not_active Application Discontinuation
- 2001-10-12 CA CA002425125A patent/CA2425125A1/en not_active Abandoned
- 2001-10-12 JP JP2002557259A patent/JP2004528283A/ja not_active Withdrawn
- 2001-10-12 AU AU2002246490A patent/AU2002246490A1/en not_active Abandoned
- 2001-10-12 US US09/976,688 patent/US6653325B2/en not_active Expired - Fee Related
- 2001-10-12 EP EP01994057A patent/EP1404326A4/en not_active Withdrawn
- 2001-10-12 WO PCT/US2001/032149 patent/WO2002056745A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002056745A2 (en) | 2002-07-25 |
| US6653325B2 (en) | 2003-11-25 |
| EP1404326A2 (en) | 2004-04-07 |
| CA2425125A1 (en) | 2002-07-25 |
| US20020049232A1 (en) | 2002-04-25 |
| JP2004528283A (ja) | 2004-09-16 |
| EP1404326A4 (en) | 2004-06-30 |
| AU2002246490A1 (en) | 2002-07-30 |
| WO2002056745A3 (en) | 2004-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020434A1 (es) | Metodo de tratamiento de la enfermedad de parkinson | |
| PE46597A1 (es) | Agonista de estrogeno | |
| ES2313079T3 (es) | Benzimidazol, benzotiazol, benzoxazol y su utilizacion como moduladores de lta4h. | |
| PE20131463A1 (es) | Piperidino-dihidrotienopirimidinas sustituidas | |
| UY26974A1 (es) | Agonistas del receptor beta3 adrenérgico y usos de los mismos | |
| PE20060988A1 (es) | Sintesis asimetrica de dihidrobenzofuranos sustituidos | |
| PE11698A1 (es) | Compuestos de 6-dimetilaminometil-1-fenil ciclohexano y procedimiento para el uso de dichos compuestos | |
| PE59999A1 (es) | Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos | |
| PE20001084A1 (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
| ATE431345T1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| DE69936848D1 (de) | Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie | |
| MX9702601A (es) | AGONISTAS beta-ADRENERGICOS HETEROCICLICOS. | |
| CN1942179A (zh) | 用于治疗不安腿综合征和成瘾症的α－氨基酰胺衍生物 | |
| PE20020917A1 (es) | Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato | |
| RS54470B1 (en) | Catecholamine derivatives useful for the treatment of Parkinson's disease | |
| WO2007002945A3 (en) | P2y6 receptor agonists for treating lung diseases | |
| AR070336A1 (es) | Derivado tiazol y su uso como inhibidor de vap-1 | |
| BRPI0418181A (pt) | emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson | |
| PE20061083A1 (es) | Composicion farmaceutica que comprende benzoxazoles sustituidos | |
| RU2012120759A (ru) | Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы | |
| BRPI0416564A (pt) | novas prostamidas para o tratamento de glaucoma e doenças relacionadas | |
| MY164007A (en) | Quinolone compound and pharmaceutical composition | |
| PE20050350A1 (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobencenos sustituidos como agonistas de 5-ht1f | |
| AR056805A1 (es) | Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados | |
| PE20040906A1 (es) | Derivados morfolinicos como agonistas de dopamina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |